VTYX - Why Is Psoriasis Player Ventyx Biosciences Stock Trading Lower Today? | Benzinga
Ventyx Biosciences Inc (NASDAQ: VTYX) released results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis.
The Phase 2 SERENITY trial of VTX958 was a 16-week, randomized, double-blind, placebo-controlled, dose-ranging trial evaluating the efficacy and safety of four oral doses of VTX958 (50 mg BID, 300 mg QD, 225 mg BID, and 300 mg BID).
The primary endpoint was the proportion of participants achieving a 75% ...